Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 141 clinical trials
Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

therapy and to determine a more appropriate interval to assess hormone therapy sensitivity in women who are undergoing surgery for HR-positive, Human epidermal growth factor receptor 2 (HER2)-negative

epidermal growth factor receptor
luminal
erbb2
progesterone receptor
breast cancer
  • 1 views
  • 12 Feb, 2022
  • 1 location
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

does not express the human epidermal growth factor receptor 2 (HER2) protein and has spread to other places in the body (metastatic), cannot be removed by surgery (unresectable), or has come back

gilbert's syndrome
epidermal growth factor
liver metastasis
gemcitabine
fulvestrant
  • 0 views
  • 22 Mar, 2022
  • 1 location
MicroRNA Profiles in Triple Negative Breast Cancer (TARMAC)

cancer such as hormone positive and Human Epidermal Growth factor 2 (HER2) positive subtypes. Chemotherapy is therefore the main choice of systemic treatment with rapid development of resistance in most

taxane
carboplatin
HER2
paclitaxel
growth factor
  • 0 views
  • 23 Mar, 2022
  • 1 location
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

This is an open, prospective and interventional clinical study. Patients with advanced Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer resistant to trastuzumab will be

  • 0 views
  • 08 Jul, 2022
  • 2 locations
AZD8186 and Paclitaxel in Advanced Gastric Cancer

models. PTEN deficiency is reported in approximately 20% of patients with gastric cancer and in 35-48% of those with human epidermal growth factor receptor 2(HER2)-positive gastric cancer. To date, there

paclitaxel
epidermal growth factor receptor
solid tumor
immunomodulator
erbb2
  • 8 views
  • 11 Feb, 2022
  • 1 location
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

taxanes based chemotherapy is usually the first choice of NACT for human epidermal growth factor receptor 2 (HER2) negative breast cancer, but there is no ideal second-line therapy for those with

  • 0 views
  • 07 Dec, 2021
  • 1 location
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

epidermal growth factor receptor 2 (HER2) negative breast cancer with progressive disease on 2 prior lines of hormonal therapy) or triple negative (ER negative/PR negative/HER2 negative, TNBC). Eighty-four

carcinoma
immunostimulant
carboplatin
breast carcinoma
mammogram
  • 3 views
  • 14 Jun, 2022
  • 7 locations
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

NSCLC.Afatinib was a 2nd-generation EGFR TKI that covalently bound and irreversibly blocked signaling through activated EGFR, human epidermal growth factor receptor 2 (HER2), and ErbB4 receptors, and the FDA has

  • 0 views
  • 27 Apr, 2022
  • 1 location
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (VISTA)

This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients

carcinoma
bladder cancer
lung cancer
kidney function test
epidermal growth factor receptor
  • 0 views
  • 17 Mar, 2022
  • 1 location
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

This study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC) and high expression of human epidermal growth factor Receptor 3 (HER3) defined as

  • 0 views
  • 22 Jul, 2021
  • 1 location